Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 836

1.

Radiation dose escalation for localized prostate cancer: intensity-modulated radiotherapy versus permanent transperineal brachytherapy.

Wong WW, Vora SA, Schild SE, Ezzell GA, Andrews PE, Ferrigni RG, Swanson SK.

Cancer. 2009 Dec 1;115(23):5596-606. doi: 10.1002/cncr.24558.

2.
3.

Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.

Pellizzon AC, Nadalin W, Salvajoli JV, Fogaroli RC, Novaes PE, Maia MA, Ferrigno R.

Radiother Oncol. 2003 Feb;66(2):167-72.

PMID:
12648788
4.

Whole pelvic radiotherapy for prostate cancer using 3D conformal and intensity-modulated radiotherapy.

Ashman JB, Zelefsky MJ, Hunt MS, Leibel SA, Fuks Z.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):765-71.

PMID:
15913914
5.

Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406.

Michalski JM, Purdy JA, Winter K, Roach M 3rd, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, Wilder RB, Hanks GE, Cox JD.

Int J Radiat Oncol Biol Phys. 2000 Jan 15;46(2):391-402.

PMID:
10661346
6.

Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.

Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI.

Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1124-9. doi: 10.1016/j.ijrobp.2007.11.044.

PMID:
18313526
7.

Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer.

Koontz BF, Chino J, Lee WR, Hahn CA, Buckley N, Huang S, Kim J, Reagan R, Joyner R, Anscher MS.

Brachytherapy. 2009 Apr-Jun;8(2):191-6. doi: 10.1016/j.brachy.2009.01.002.

PMID:
19433320
8.

Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma.

Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, Venkatramen ES, Leibel SA.

Cancer. 1999 Jun 1;85(11):2460-8.

PMID:
10357419
9.

[Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer].

Aillères N, Azria D, Thézenas S, Barbier N, Fenoglietto P, Delard R, Hay MH, Dubois JB.

Cancer Radiother. 2004 Apr;8(2):59-69. English, French.

PMID:
15063872
10.

Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models.

King CR, DiPetrillo TA, Wazer DE.

Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):165-72.

PMID:
10656389
11.

Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.

Forsythe K, Blacksburg S, Stone N, Stock RG.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):630-5. doi: 10.1016/j.ijrobp.2011.06.2013. Epub 2011 Nov 16.

PMID:
22099032
12.

Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.

Mohammed N, Kestin L, Ghilezan M, Krauss D, Vicini F, Brabbins D, Gustafson G, Ye H, Martinez A.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):204-12. doi: 10.1016/j.ijrobp.2010.10.009. Epub 2010 Dec 16.

PMID:
21167653
13.
15.

Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancer.

Kupelian PA, Reddy CA, Carlson TP, Altsman KA, Willoughby TR.

Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):904-12.

PMID:
12095556
16.
17.

Toxicity following high-dose three-dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer.

Shu HK, Lee TT, Vigneauly E, Xia P, Pickett B, Phillips TL, Roach M.

Urology. 2001 Jan;57(1):102-7.

PMID:
11164152
18.

Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.

Deville C, Both S, Hwang WT, Tochner Z, Vapiwala N.

Int J Radiat Oncol Biol Phys. 2010 Nov 1;78(3):763-72. doi: 10.1016/j.ijrobp.2009.08.043. Epub 2010 Feb 18.

PMID:
20171807
19.

Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.

Michalski JM, Winter K, Purdy JA, Parliament M, Wong H, Perez CA, Roach M, Bosch W, Cox JD.

Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):706-13.

PMID:
15936549
20.

Supplemental Content

Support Center